Top

Published in:

18-11-2023 | Huntington's Disease | Letter to the Editors

Plasma GFAP and its association with disease severity in Huntington’s disease

Authors: Kübra Tan, Melanie Alpaugh, Nicholas J. Ashton, Sylvain Chouinard, Roger A. Barker, Kaj Blennow, Henrik Zetterberg, Francesca Cicchetti, Andréa L. Benedet

Published in: Journal of Neurology | Issue 4/2024

Excerpt

Dear Sirs, …

Available only for authorised users

Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Prim 1(1):15005CrossRefPubMed

Pavese N, Gerhard A, Tai YF et al (2006) Microglial activation correlates with severity in Huntington disease. Clin PET Study 66(11):1638–1643

Tai YF, Pavese N, Gerhard A et al (2007) Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain 130(Pt 7):1759–1766CrossRefPubMed

Jurcau A (2022) Molecular pathophysiological mechanisms in Huntington’s disease. Biomedicines 10(6):1432. https://doi.org/10.3390/biomedicines10061432CrossRefPubMedPubMedCentral

Sapp E, Kegel K, Aronin N et al (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60(2):161–172CrossRefPubMed

Al-Dalahmah O, Sosunov AA, Shaik A et al (2020) Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol Commun 8(1):19CrossRefPubMedPubMedCentral

Benraiss A, Mariani JN, Osipovitch M et al (2021) Cell-intrinsic glial pathology is conserved across human and murine models of Huntington’s disease. Cell Rep 36(1):109308CrossRefPubMed

Wood TE, Barry J, Yang Z, Cepeda C, Levine MS, Gray M (2019) Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington’s disease mouse model. Hum Mol Genet 28(3):487–500PubMed

Sampaio C, Wilkinson HA (2023) Facilitating Huntington’s disease research: plasma neurofilament levels as a promising enrichment biomarker for HD-ISS stage 1. EBioMedicine 94:104710CrossRefPubMedPubMedCentral

10.

Parkin GM, Corey-Bloom J, Snell C, Castleton J, Thomas EA (2021) Plasma neurofilament light in Huntington’s disease: a marker for disease onset, but not symptom progression. Parkinsonism Relat Disord 87:32–38CrossRefPubMedPubMedCentral

11.

Benedet AL, Milà-Alomà M, Vrillon A et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78(12):1471–1483CrossRefPubMed

12.

Azzolini F, Gilio L, Pavone L et al (2022) Neuroinflammation is associated with GFAP and sTREM2 levels in multiple sclerosis. Biomolecules 12(2):222. https://doi.org/10.3390/biom12020222CrossRefPubMedPubMedCentral

13.

van der Naalt J, Timmerman ME, de Koning ME et al (2017) Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study. Lancet Neurol 16(7):532–540CrossRefPubMed

14.

You H, Wu T, Du G et al (2021) Evaluation of blood glial fibrillary acidic protein as a potential marker in Huntington’s disease. Front Neurol 12:779890CrossRefPubMedPubMedCentral

15.

Denis HL, Lamontagne-Proulx J, St-Amour I et al (2018) Platelet-derived extracellular vesicles in Huntington’s disease. J Neurol 265(11):2704–2712CrossRefPubMed

16.

Denis HL, Alpaugh M, Alvarez CP et al (2023) Detection of antibodies against the huntingtin protein in human plasma. Cell Mol Life Sci 80(2):45CrossRefPubMedPubMedCentral

17.

Unified Huntington’s Disease Rating Scale (1996) reliability and consistency. Huntington Study Group Mov Disord 11(2):136–142

18.

Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41(5):689–692CrossRefPubMed

19.

Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577–589CrossRefPubMed

Title: Plasma GFAP and its association with disease severity in Huntington’s disease
Authors: Kübra Tan
Melanie Alpaugh
Nicholas J. Ashton
Sylvain Chouinard
Roger A. Barker
Kaj Blennow
Henrik Zetterberg
Francesca Cicchetti
Andréa L. Benedet
Publication date: 18-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Huntington's Disease
Biomarkers
Published in: Journal of Neurology / Issue 4/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12109-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasma GFAP and its association with disease severity in Huntington’s disease

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2024

Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study

Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

Nutritional interventions for multiple sclerosis

Myelitis as a side effect of tofersen therapy in ALS